Arcturus Therapeutics Holdings (ARCT) Invested Capital (2018 - 2026)

Arcturus Therapeutics Holdings has reported Invested Capital for 9 years, with the latest figure at $191.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 18.14% year-over-year to $191.4 million; the trailing twelve-month figure through Mar 2026 stood at $191.4 million (down 18.14% YoY), and the FY2025 full-year result was $214.0 million, down 11.2% from the prior year.
• Invested Capital for Q1 2026 stood at $191.4 million, down from $214.0 million in the prior quarter.
• The five-year high for Invested Capital was $329.2 million in Q1 2023, with the low at $173.4 million in Q3 2022.
• Historically, Invested Capital has averaged $246.9 million across 5 years, with a median of $241.0 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital plunged 41.25% — and 2023, when it soared 63.56%.
• Arcturus Therapeutics Holdings' Invested Capital stood at $320.7 million in 2022, then fell by 13.16% to $278.5 million in 2023, then fell by 13.48% to $241.0 million in 2024, then fell by 11.2% to $214.0 million in 2025, then declined by 10.57% to $191.4 million in 2026.
• The last three Invested Capital figures came in at $191.4 million (Q1 2026), $214.0 million (Q4 2025), and $224.6 million (Q3 2025), per Business Quant data.